利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.017 秒)

    COMPOSITIONS FOR PREVENTING AND/OR TREATING AN INFECTION BY AN HIV-1 VIRUS
    1.
    发明申请
    COMPOSITIONS FOR PREVENTING AND/OR TREATING AN INFECTION BY AN HIV-1 VIRUS 有权
    用于预防和/或治疗HIV-1病毒感染的组合物

    公开(公告)号：US20140037666A1

    公开(公告)日：2014-02-06

    申请号：US14111790

    申请日：2012-04-13

    申请人： Patrice Debre ,  Vincent Vieillard

    发明人： Patrice Debre ,  Vincent Vieillard

    IPC分类号： C07K7/08 ,  A61K45/06 ,  G01N33/569 ,  A61K39/12

    CPC分类号： C07K7/08 ,  A61K39/00 ,  A61K39/12 ,  A61K45/06 ,  A61K2039/55566 ,  A61K2039/6081 ,  C07K14/005 ,  C07K16/1063 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/76 ,  C12N2740/16122 ,  C12N2740/16134 ,  G01N33/56988 ,  G01N2333/16 ,  G01N2469/20

    摘要： The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S—X1-X2-X3-K—X4-Ct (I) [SEQ ID No 1], wherein—Nt consists of a peptide having from 0 to 50 amino acids in length, —Ct consists of a peptide having from 0 to 50 amino acids in length, —each of X1 to X4 consists of an amino acid residue, wherein: —(i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, —(i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, —(i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, —(i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that—three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and—the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in its meaning (i), for preventing and/or treating an infection of an individual with an HIV-1 virus.

    摘要翻译： 本发明涉及包含以下式（I）的抗原肽的免疫原性组合物：Nt-S-X1-X2-X3-K-X4-Ct（I）[SEQ ID No.1]，其中-Nt由 具有0至50个氨基酸长度的肽，-Ct由长度为0至50个氨基酸的肽组成，每个X1至X4由氨基酸残基组成，其中：（i）X1表示特异性 氨基酸W或（ii）X1表示除W以外的任何氨基酸残基， - （i）X2表示特定氨基酸S或（ii）X2表示除S以外的任何氨基酸残基，（i）X3表示特定氨基酸 N或（ii）X3表示除N以外的任何氨基酸残基， - （i）X4表示特定氨基酸S或（ii）X4表示除S以外的任何氨基酸残基，条件是四个氨基酸中的三个 残基X1，X2，X3和X4表示其各自含义（i）中定义的特定氨基酸，X1至X4中的剩余氨基酸残基表示除特定氨基酸之外的任何氨基酸残基 d限定在其含义（i）中，用于预防和/或治疗患有HIV-1病毒的个体的感染。

    Compositions for preventing and/or treating an infection by an HIV-1 virus
    2.
    发明授权
    Compositions for preventing and/or treating an infection by an HIV-1 virus 有权

    公开(公告)号：US10174080B2

    公开(公告)日：2019-01-08

    申请号：US15712195

    申请日：2017-09-22

    申请人： Patrice Debre ,  Vincent Vieillard

    发明人： Patrice Debre ,  Vincent Vieillard

    IPC分类号： A61K39/00 ,  C12Q1/68 ,  C07K14/00 ,  A61K39/395 ,  C07H21/04 ,  C07K7/08 ,  C07K16/10 ,  C07K14/005 ,  A61K39/12 ,  A61K45/06 ,  G01N33/569

    摘要： The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S-X1-X2-X3-K-X4-Ct (I) [SEQ ID No 1], wherein Nt consists of a peptide having from 0 to 50 amino acids in length, Ct consists of a peptide having from 0 to 50 amino acids in length, each of X1 to X4 consists of an amino acid residue, wherein: (i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, (i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, (i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, (i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in its meaning (i), for preventing and/or treating an infection of an individual with an HIV-1 virus.

    Therapeutic vaccination method, mutated peptides of hiv reverse transciptase and their use for vaccination and diagnostic purposes
    4.
    发明申请
    Therapeutic vaccination method, mutated peptides of hiv reverse transciptase and their use for vaccination and diagnostic purposes 审中-公开
    治疗性接种方法，hiv逆转录酶的突变肽及其用于疫苗接种和诊断目的

    公开(公告)号：US20050074463A1

    公开(公告)日：2005-04-07

    申请号：US10489123

    申请日：2001-09-14

    申请人： Brigitte Autran ,  Assia Samri ,  Patrice Debre ,  Vincent Calvez ,  Christine Katlama ,  Gaby Haas

    发明人： Brigitte Autran ,  Assia Samri ,  Patrice Debre ,  Vincent Calvez ,  Christine Katlama ,  Gaby Haas

    IPC分类号： A61K38/00 ,  A61K39/00 ,  A61K39/39 ,  A61K48/00 ,  A61P31/00 ,  A61P31/18 ,  A61P35/00 ,  C07K7/06 ,  C07K7/08 ,  C12N9/12 ,  C12Q1/02 ,  A61K39/21

    CPC分类号： C12N9/1276 ,  A61K39/00 ,  C12N2799/021

    摘要： The invention concerns treatment of infectious and tumoral pathologies comprising a anti-infective and/or anti-tumoral chemotherapeutic treatment phase inducing resistance mutations and a therapeutic vaccination phase directed against said resistance mutations and the agents used in said treatment More particularly, the invention concerns peptides of 8 to 80 amino acids of the HIV reverse transcriptase sequence and comprising at least a mutation with respect to said wild sequence of said enzyme, mutation induced in response to treatments by nucleoside and non-nucleoside analogues of the HIV reverse transcriptase. The invention also concerns a pharmaceutical composition or vaccine based on said peptides, for inducing an immune response specific of said mutated sequences and for enhancing or prolonging the efficiency of treatments with nucleoside or non-nucleoside analogues of the HIV reverse transcriptase. The invention further concerns epitopes derived from said peptide sequences to evaluate the specific immune response following the vaccine injection.

    摘要翻译： 本发明涉及感染性和肿瘤病理学的治疗，其包括诱导抗性突变的抗感染和/或抗肿瘤化学治疗期，以及针对所述抗性突变的治疗性接种期和用于所述治疗的药剂。更具体地，本发明涉及肽 所述HIV逆转录酶序列的8至80个氨基酸，并且对于所述酶的所述野生型序列至少包含突变，所述突变响应于HIV逆转录酶的核苷和非核苷类似物的处理而诱导。 本发明还涉及基于所述肽的药物组合物或疫苗，用于诱导所述突变序列特异性的免疫应答，并且用于增强或延长用HIV逆转录酶的核苷或非核苷类似物处理的效率。 本发明还涉及来自所述肽序列的表位，以评估疫苗注射后的特异性免疫应答。

    COMPOSITIONS FOR PREVENTING AND/OR TREATING AN INFECTION BY AN HIV-1 VIRUS
    5.
    发明申请
    COMPOSITIONS FOR PREVENTING AND/OR TREATING AN INFECTION BY AN HIV-1 VIRUS 有权
    用于预防和/或治疗HIV-1病毒感染的组合物

    公开(公告)号：US20160031943A1

    公开(公告)日：2016-02-04

    申请号：US14870287

    申请日：2015-09-30

    申请人： Patrice DEBRE ,  Vincent VIEILLARD

    发明人： Patrice DEBRE ,  Vincent VIEILLARD

    IPC分类号： C07K7/08 ,  G01N33/569

    CPC分类号： C07K7/08 ,  A61K39/00 ,  A61K39/12 ,  A61K45/06 ,  A61K2039/55566 ,  A61K2039/6081 ,  C07K14/005 ,  C07K16/1063 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/76 ,  C12N2740/16122 ,  C12N2740/16134 ,  G01N33/56988 ,  G01N2333/16 ,  G01N2469/20

    摘要： The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S-X1-X2-X3-K-X4-Ct (I) [SEQ ID No 1], wherein —Nt consists of a peptide having from 0 to 50 amino acids in length, —Ct consists of a peptide having from 0 to 50 amino acids in length, —each of X1 to X4 consists of an amino acid residue, wherein: —(i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, —(i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, —(i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, —(i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that —three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and —the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in its meaning (i), for preventing and/or treating an infection of an individual with an HIV-1 virus.

    摘要翻译： 本发明涉及包含以下式（I）的抗原肽的免疫原性组合物：Nt-S-X1-X2-X3-K-X4-Ct（I）[SEQ ID No.1]，其中-Nt由 具有0至50个氨基酸长度的肽，-Ct由长度为0至50个氨基酸的肽组成，每个X1至X4由氨基酸残基组成，其中：（i）X1表示特异性 氨基酸W或（ii）X1表示除W以外的任何氨基酸残基， - （i）X2表示特定氨基酸S或（ii）X2表示除S以外的任何氨基酸残基，（i）X3表示特定氨基酸 N或（ii）X3表示除N以外的任何氨基酸残基， - （i）X4表示特异性氨基酸S或（ii）X4表示除S以外的任何氨基酸残基，条件是 - 四个氨基酸 残基X1，X2，X3和X4表示其各自含义（i）中定义的特定氨基酸，X1至X4中的剩余氨基酸残基表示除t之外的任何氨基酸残基 其含义（i）中定义的特异性氨基酸残基用于预防和/或治疗HIV-1病毒感染个体。

    Maturation of hemopoietic cells
    8.
    发明授权
    Maturation of hemopoietic cells 失效
    HEMOPOIETIC细胞的成熟

    公开(公告)号：US5246699A

    公开(公告)日：1993-09-21

    申请号：US781248

    申请日：1991-12-30

    申请人： Patrice Debre ,  Mohammad D. Mossalayi

    发明人： Patrice Debre ,  Mohammad D. Mossalayi

    IPC分类号： A61K38/00 ,  A61K38/17 ,  A61K38/20 ,  A61P7/00 ,  C07K14/735

    CPC分类号： C07K14/70535 ,  A61K38/2006 ,  A61K38/00 ,  Y10S435/975

    摘要： The invention concerns the use of IgE-binding factor (IgE-bf) for the stimulation of the maturation, i.e. of the differentiation and proliferation, of myeloid precursor cells in context with interleukin-1 (IL-1). The invention further concerns a a pharmaceutical preparation comprising IgE-bf either alone or in combination with IL-1 for the treatment or prevention of diseases by stimulating the maturation of myeloid precursor cells.

    摘要翻译： PCT No.PCT / EP91 / 00821 Sec。 371日期1991年12月30日 102（e）1991年12月30日PCT PCT 1991年4月30日PCT。 出版物WO91 / 16915 PCT 1991年11月14日，本发明涉及IgE结合因子（IgE-bf）用于刺激髓系前体细胞的成熟（即分化和增殖）在白介素-1（IL-1） ）。 本发明还涉及包含单独或与IL-1组合的IgE-bf的药物制剂，用于通过刺激骨髓前体细胞的成熟来治疗或预防疾病。